EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million

EQT Sweden

Proceeds will be used to enable key late-stage clinical trial readouts for assets across several underserved neurological diseases with high unmet medical need.EQT Life Sciences has led the extension, and joins a consortium of prominent global biotechnology investors.The investment builds on EQT Life Sciences' previous successful partnership with neurology-focused repeat entrepreneur and Noema Pharma CEO Ilise Lombardo, MDView original content:https://www.prnewswire.co.uk/news-releases/eqt-life-sciences-leads-series-b-extension-in-noema-pharma-raising-total-series-b-financing-to-chf-130-million-302328750.html